✅ Medically reviewed by Dr. Tom Biernacki, DPM, FACFAS
Board-certified podiatric surgeon · 3,000+ procedures · The Private Practice
Last reviewed: May 17, 2026
Quick answer: Total cholesterol is a poor predictor of cardiovascular risk. What matters is the type and size of lipid particles, your triglycerides-to-HDL ratio, ApoB particle count, Lp(a) levels, and your inflammatory burden. Most standard lipid panels miss the most important predictors — and many people on statins still have high residual cardiovascular risk because the real drivers aren’t being addressed.
What You’ll Learn
- The biggest myths about cholesterol and heart disease
- ApoB: the metric your doctor probably isn’t measuring
- Lp(a): the inherited cardiovascular risk factor
- The triglyceride-to-HDL ratio: the most actionable lipid metric
- Inflammation as the true driver of cardiovascular disease
- The truth about dietary fat, cholesterol, and heart disease
- Frequently asked questions
Cardiovascular disease is still the number one killer in the developed world — despite decades of cholesterol-lowering drugs, low-fat dietary guidelines, and billions in research funding. Something in the standard model isn’t working for enough people. When I started applying advanced lipid testing and functional cardiovascular assessment to my own labs and to patients, the picture that emerged was very different from the “total cholesterol below 200” framework most people have been operating under. The science has moved well past LDL as the primary villain — and understanding where it’s moved gives you meaningful tools to actually reduce your risk, not just lower a lab number.
The Biggest Myths About Cholesterol and Heart Disease
Myth 1: High total cholesterol causes heart disease. The reality is more nuanced. The Framingham Heart Study — the foundational cardiovascular epidemiology study — found that total cholesterol was not a strong predictor of cardiovascular events in people over 50. More recent data from the PURE study and others shows that in many populations, higher total cholesterol is associated with lower all-cause mortality. What predicts cardiovascular events is the composition and context of that cholesterol — specifically, the number of atherogenic particles, the presence of inflammation, the degree of oxidative stress, and insulin resistance.
Myth 2: LDL is always bad. LDL cholesterol is not a single entity — it encompasses a spectrum of particle sizes and densities with very different atherogenic properties. Small, dense LDL particles (Pattern B) are far more atherogenic than large, buoyant LDL particles (Pattern A), and the standard LDL measurement doesn’t distinguish between them. Two people can have identical LDL cholesterol values and profoundly different cardiovascular risk profiles based on particle type. This is why LDL alone is a poor predictor — and why ApoB measurement is a superior alternative.
Key takeaway: Total cholesterol and standard LDL measurements were developed in an era before we understood lipid particle biology. The markers that actually predict cardiovascular events — ApoB, Lp(a), triglyceride:HDL ratio, oxidized LDL, hs-CRP — are rarely included in routine panels.
ApoB: The Metric Your Doctor Probably Isn’t Measuring
Apolipoprotein B (ApoB) is a protein present on every atherogenic lipoprotein particle — LDL, VLDL, IDL, Lp(a), and chylomicron remnants. Unlike LDL-cholesterol, which measures the cholesterol content of LDL particles, ApoB directly measures the number of atherogenic particles in circulation. Since it’s the particle itself (not its cholesterol cargo) that embeds in arterial walls and initiates plaque formation, particle count is mechanistically more relevant than particle cholesterol content.
The clinical evidence supports this: multiple large studies have shown that ApoB is a superior predictor of cardiovascular events compared to LDL-cholesterol. The INTERHEART study — involving 15,152 cases in 52 countries — found that the ApoB-to-ApoA1 ratio was the single strongest lipid-related predictor of myocardial infarction, outperforming the total cholesterol-to-HDL ratio, LDL, and all other standard lipid measures. Target ApoB values for most adults: below 90 mg/dL for moderate risk, below 80 mg/dL for high risk, below 70 mg/dL for those with established cardiovascular disease. Your lab can measure ApoB from a standard blood draw — it just isn’t included in routine panels. Ask for it.
Lp(a): The Inherited Cardiovascular Risk Factor Almost Nobody Knows About
Lipoprotein(a) — Lp(a) — is an LDL particle with an additional protein (apolipoprotein(a)) attached. It is largely genetically determined (80-90% heritable), meaning diet and lifestyle changes have minimal effect on it. Elevated Lp(a) — present in approximately 20% of the population — is associated with a 2–4x increased risk of heart attack and stroke, independent of LDL levels. Critically, many people with “normal” LDL cholesterol have significantly elevated Lp(a) and are completely unaware of their risk because it’s not part of standard lipid panels.
The Lp(a) risk threshold is generally considered to be above 50 mg/dL (or above 125 nmol/L), though risk increases linearly with level. Lp(a) measurement should be done at least once in every adult — it’s a low-cost, one-time test that identifies a clinically significant hereditary risk factor that otherwise remains hidden. While lifestyle modifications minimally affect Lp(a) levels, knowing it’s elevated changes the overall cardiovascular risk calculation and may justify more aggressive management of other modifiable risk factors (LDL, blood pressure, inflammation, insulin resistance). Aspirin has modest evidence for Lp(a)-mediated risk; dedicated Lp(a)-lowering drugs are currently in Phase 3 trials.
The Triglyceride-to-HDL Ratio: The Most Actionable Lipid Metric
The triglyceride-to-HDL ratio (TG:HDL) is one of the most clinically useful, immediately actionable lipid metrics in standard blood panels — and it’s almost never discussed. A ratio below 2.0 (US units, mg/dL) is associated with predominantly large, buoyant LDL particles (cardioprotective Pattern A). A ratio above 3.5 is associated with predominantly small, dense LDL particles (atherogenic Pattern B), insulin resistance, and high metabolic risk. A ratio above 5.0 is a strong marker of significant metabolic dysfunction, even in people with “normal” total cholesterol. This ratio is computable from standard lipid panels — you just divide your triglycerides by your HDL.
The TG:HDL ratio is also highly responsive to lifestyle intervention — making it the most actionable lipid metric available. High TG:HDL ratios are primarily driven by insulin resistance, excess dietary refined carbohydrates and added sugars, physical inactivity, excess alcohol, and visceral adiposity. Time-restricted eating (as discussed in our intermittent fasting article), reducing refined carbohydrates, increasing omega-3 intake (our omega-3 article covers the evidence), and resistance training can meaningfully improve this ratio within weeks. Unlike Lp(a) or genetics, this is a direct lever you can pull.
Inflammation as the True Driver of Cardiovascular Disease
The most significant paradigm shift in cardiovascular medicine over the past 20 years is the recognition that atherosclerosis is fundamentally an inflammatory disease — not a cholesterol storage disease. LDL particles are necessary but not sufficient for plaque formation. LDL particles become atherogenic when they are oxidized — and oxidation is driven by inflammatory processes. This is why hs-CRP (high-sensitivity C-reactive protein) has become one of the most important cardiovascular biomarkers: it measures the systemic inflammation that drives LDL oxidation, endothelial dysfunction, and plaque instability.
The landmark JUPITER trial demonstrated that in people with “normal” LDL but elevated hs-CRP (>2 mg/L), statin therapy (specifically rosuvastatin — which reduces both LDL and inflammation) reduced major cardiovascular events by 44%. The anti-inflammatory mechanism of statins may be as important as their LDL-lowering effect. This has profound implications: the real cardiovascular risk profile is not fully captured by lipid numbers alone. Measuring hs-CRP alongside lipids (as detailed in our blood test guide) gives a far more complete picture — and targeting inflammation through diet, exercise, omega-3s, and sleep is a direct cardiovascular risk reduction strategy.
Key takeaway: Atherosclerosis is primarily an inflammatory disease. LDL cholesterol is a contributor but not the sole driver. Measuring and reducing hs-CRP, oxidized LDL, and insulin resistance addresses the upstream cause — not just a downstream marker.
The Truth About Dietary Fat, Cholesterol, and Heart Disease
The dietary cholesterol hypothesis — that eating cholesterol-rich foods raises blood cholesterol and causes heart disease — has largely been overturned. The 2015-2020 Dietary Guidelines for Americans removed the previous 300mg/day dietary cholesterol limit, reflecting the scientific consensus that for most people, dietary cholesterol has minimal effect on blood cholesterol levels because the liver compensates by producing less. Eggs — long vilified — have been largely exonerated in prospective studies, with a 2020 meta-analysis in the British Medical Journal finding no significant association between egg consumption and cardiovascular disease in most populations.
The dietary factors that do meaningfully worsen cardiovascular risk: trans fats (now largely eliminated from the food supply but still present in some processed foods), excess refined carbohydrates and added sugars (which raise triglycerides and worsen insulin resistance), and highly processed foods that drive oxidative stress and systemic inflammation. The Mediterranean dietary pattern — rich in olive oil, fish, legumes, vegetables, and moderate red wine — has the strongest evidence base for cardiovascular protection, primarily through anti-inflammatory mechanisms rather than cholesterol effects. This is a meaningful distinction: the diet that protects your heart does so through reducing inflammation and improving insulin sensitivity, not primarily through lowering total cholesterol.
Frequently Asked Questions
Should I be on a statin if my LDL is high?
This decision should be made based on your complete cardiovascular risk profile — not LDL in isolation. The ACC/AHA cardiovascular risk calculator incorporates age, sex, race, total and HDL cholesterol, blood pressure, diabetes status, and smoking. A 10-year cardiovascular event risk above 7.5% generally supports statin consideration. However, for personalized decision-making, knowing your ApoB, Lp(a), hs-CRP, coronary artery calcium (CAC) score, and metabolic status provides a much more complete picture. The CAC score in particular — a CT scan measuring calcified plaque — is the strongest available predictor of future cardiovascular events and can reclassify risk significantly in both directions. A CAC score of zero in someone with elevated LDL may justify watchful waiting over statin therapy; a high CAC score changes the urgency significantly.
What’s the ideal cholesterol profile?
Rather than focusing on total cholesterol, the markers I prioritize in patients: ApoB below 80–90 mg/dL; Lp(a) below 50 mg/dL; triglycerides below 100 mg/dL; HDL above 50 mg/dL (women) or 40 mg/dL (men); TG:HDL ratio below 2.0; hs-CRP below 1.0 mg/L; fasting insulin below 7 μIU/mL. These metrics together give a far more complete cardiovascular risk picture than the standard lipid panel. For context, many people with “normal” total cholesterol and LDL fail to meet several of these targets — and many people with “high” LDL meet all of them.
What raises HDL cholesterol?
HDL is highly responsive to lifestyle: regular aerobic exercise (particularly high-intensity interval training) is the most potent HDL raiser, consistently producing 5–10% increases. Moderate alcohol consumption raises HDL — though the net health effect of alcohol is complex and generally negative for other reasons. Dietary fat, particularly monounsaturated fat (olive oil, avocados) and omega-3 fatty acids, raises HDL. Smoking cessation raises HDL. Refined carbohydrate reduction improves HDL by reducing triglycerides (the two are inversely related). Niacin (vitamin B3) raises HDL effectively but has shown inconsistent cardiovascular outcome benefits in trials despite the HDL elevation — a reminder that surrogate marker improvement doesn’t always translate to clinical outcomes.
If your advanced lipid panel shows elevated triglycerides, omega-3 EPA+DHA has among the strongest triglyceride-reduction data of any supplement — but form and dose matter significantly. Read why your omega-3 supplement is probably failing you for the triglyceride-specific protocol. Chronic inflammation — measured by hs-CRP and IL-6 — is the mechanism that converts elevated LDL-P into arterial plaque, covered in the silent driver of heart disease, diabetes, and Alzheimer's. For a plain-English guide to interpreting your full panel, how to read blood test results walks through the reference ranges I use clinically.
The Bottom Line
Standard cholesterol testing provides a fraction of the information needed to accurately assess cardiovascular risk. If your doctor has only ever checked total cholesterol, LDL, HDL, and triglycerides — you are missing ApoB, Lp(a), particle size, oxidized LDL, and inflammatory markers that collectively provide a far more accurate risk picture. The good news: the lifestyle interventions that genuinely reduce cardiovascular risk — anti-inflammatory diet, resistance training, omega-3 supplementation, sleep optimization, stress reduction — address the upstream drivers more comprehensively than any single number on a standard panel. I had my own advanced cardiovascular panel done and the picture was very different from what the standard panel suggested. That’s why I believe every adult should know these numbers. That’s the honest truth.
Sources
- Yusuf S, et al. “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study).” The Lancet. 2004. PubMed
- Ridker PM, et al. “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER).” NEJM. 2008. PubMed
- Sniderman AD, et al. “A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.” Circulation. 2011. PubMed
- Nordestgaard BG, et al. “Lipoprotein(a) as a cardiovascular risk factor.” European Heart Journal. 2010. PubMed
- Hu FB, et al. “Dietary fat intake and the risk of coronary heart disease in women.” NEJM. 1997. PubMed
- Estruch R, et al. “Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED).” NEJM. 2018. PubMed
Want Your Advanced Cardiovascular Panel Interpreted?
ApoB, Lp(a), hs-CRP, CAC score — these are the metrics that give you a real cardiovascular risk picture. Book a consultation with Dr. Tom Biernacki for a comprehensive review and a protocol built around your results.
Board-certified DPM, FACFAS · Functional medicine perspective · 3,000+ procedures
Related Articles
- Insulin Resistance: Symptoms, Causes & Reversal
- Omega-3 EPA/DHA Fish Oil: Dose & Evidence
- Chronic Inflammation: Causes & Solutions
Dive Deeper
- The 5 Lab Tests Every Person Over 35 Should Demand From Their Doctor
- How to Read Blood Test Results: A Surgeon’s Plain-English Guide
- Insulin Resistance: Why 40% of Adults Have It and Don’t Know It
- Anti-Inflammatory Diet: The Evidence-Based Protocol to Lower Inflammation
- Inflammation Biomarkers: Comprehensive Testing Panel Beyond Standard Care